Innovation to address antimicrobial resistance in Neisseria gonorrhoeae
Antimicrobial resistance (AMR) in sexually transmitted infections (STIs) is a major public health threat, with Neisseria gonorrhoeae designated as a “high priority antibiotic resistant pathogen” by the World Health Organization (WHO).
In 2016, WHO estimated that there were 87 million cases among adults worldwide. The complications of gonorrhoea disproportionately affect women: pelvic inflammatory disease, ectopic pregnancy and infertility, and increased transmission and acquisition of HIV. The webinar discussed priority initiatives and innovations to control the spread and impact of gonococcal antimicrobial resistance (AMR).
• Yamuna Mundade, Department of Global HIV, Hepatitis and STI Programmes, WHO
• Meg Doherty, Director, Department of Global HIV, Hepatitis and STI Programmes, WHO
• Haileyesus Getahun, Director of Global Coordination & Partnership on AMR, WHO
• Teodora Wi, Medical Officer, Department of Global HIV, Hepatitis and STI Programmes, WHO
• Magnus Unemo, Director, WHO CC for Gonorrhoea and other STIs, Orebro University Hosp., Sweden
• Emily Weston, STI Surveillance, Division of STI Prevention, US CDC
• Seamus O’Brien, Director of Research & Development, GARDP
• Cecilia Ferreyra, Head of AMR Programme, FIND
• Sami Gottlieb, Medical Officer, Department of Reproductive Health and Research, WHO